Mayzent

Culminating a month that saw mostly favorable FDA verdicts, Novartis AG (NYSE: NVS) announced regulatory approval for its multiple sclerosis drug. What Happened Swiss pharma giant Novartis announced Tuesday evening the FDA greenlighted its oral drug to treat adults with relapsing forms of multiple...